



**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 4

Complete if Known

Application Number	10/724,301
Filing Date	November 26, 2003
First Named Inventor	Barbara Enenkel
Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	1/1411

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS


Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² Number ³ Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
		WO 99/53046	10/21/1999	Chiron Corporation		

Examiner Signature	<i>W. A. W. W. W.</i>	Date Considered	03/06/06
--------------------	-----------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.




INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/724,301
				Filing Date	November 26, 2003
				First Named Inventor	Barbara Enenkel
				Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	2	of	4	Attorney Docket Number	1/1411

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
dw		J. BLAZQUEZ ET AL; Mutations in the aphA-2 gene of transposon Tn5 mapping within the regions highly conserved in aminoglycoside-phosphotransferases strongly reduce aminoglycoside resistance; Molecular Microbiology (1991) Vol. 5 No. 6 pages 1511-1518; National Library of Medicine	
dw		PAUL R. THOMPSON ET AL; The COOH Terminus of Aminoglycoside Phosphotransferase (3')-IIIa Is Critical for Antibiotic Recognition and Resistance; The Journal of Biological Chemistry Vol. 274 No. 43 pages 30697-30706 (1999); American Soc. for Biochemistry and Molecular Biology, Inc.	
dw		MARIANNE Z. METZ ET AL; Construction and Characterization of Single-Transcript Tricistronic Retroviral Vectors Using Two Internal Ribosome Entry Sites; Somatic Cell and Molecular Genetics (1998) Vol. 24 No. 1 Pages 53-69; Plenum Publishing Corp.	
dw		HITOSHI NIWA ET AL; Efficient selection for high-expression transfectants with a novel eukaryotic vector; Gene (1991) Vol. 108 pages 193-200; Elsevier Science Publishers B.V.	
dw		RICHARD L. YENOFKY ET AL; A mutant neomycin phosphotransferase II gene reduces the resistance of transformants to antibiotic selection pressure; Biochemistry (May 1990) Vol. 87 pages 3435-3439; Proc. Natl Acad Science	
dw		WAI-CHING HON ET AL; Structure of an Enzyme Required for Aminoglycoside Antibiotic Resistance Reveals Homology to Eukaryotic Protein Kinases; Cell (June 13, 1997) Vol. 89 pages 887-895; Cell Press	
dw		CORD HEMANN ET AL; High Copy Expression Vector Based on Amplification-Promoting Sequences; DNA and Cell Biology (1994) Vol. 13 No. 4 pages 437-445; Mary Ann Leibert Inc Publishers	
dw		ROLF G. WERNER ET AL; Appropriate Mammalian Expression Systems for Biopharmaceuticals; Drug Research (1998) Vol. 48(II) No. 8 pages 870-880; Sonderdruck/ Reprint	
dw		GAIL URLAUB ET AL; Deletion of the Diploid Dihydrofolate Reductase Locus from Cultured Mammalian Cells; Cell (1983) Vol. 33 pages 405-412; Department of Biological Sciences, Columbia University	
dw		YOSHIKAZU SUGIMOTO ET AL; Efficient Expression of Drug-selectable Genes in Retroviral Vectors under Control of an Internal Ribosome Entry Site; Bio/Technology (July 1994) Vol. 12 pages 694-698; National Cancer Institute	

Examiner Signature	<i>M. A. Velez</i>	Date Considered	03/06/06
--------------------	--------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 4

Complete If Known

Application Number	10/724,301
Filing Date	November 26, 2003
First Named Inventor	Barbara Enenkel
Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	1/1411

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
dw		K.J. SHAW ET AL; Molecular Genetics of Aminoglycoside Resistance Genes and Familial Relationships of the Aminoglycoside-Modifying Enzymes; Microbiological Reviews (Mar. 1993) Vol. 57 No. 1 pages 138-163; American Society for Microbiology	
dw		N. RAMESH ET AL; High-titer bicistronic retroviral vectors employing foot-and-mouth disease virus internal ribosome entry site; Nucleic Acids Research (1996) Vol. 24 No. 14 pages 2697-2700; Oxford University Press	
dw		JERRY PELLETIER ET AL; Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA; Nature (July 1998) Vol. 334 pages 320-325; McGill Cancer Center, McGill University, Montreal Canada	
dw		D.D. MOSSER ET AL; Use of a Dicistronic Expression Cassette Encoding the Green Fluorescent Protein for the Screening and selection of Cells Expressing Inducible Gene Products; Biotechniques (January 1997) Vol. 22 pages 150-161; National Research Council, Montreal Canada	
dw		RICHARD A. MORGAN ET AL; Retroviral vectors containing putative internal ribosome entry sites: development of a polycistronic gene transfer system and applications to human gene therapy; Nucleic Acids Research (1992) Vol. 20 No. 6 pages 1293-1299; Molecular Hematology Branch	
dw		LUCIA MONACO ET AL; Expression of recombinant human granulocyte colony-stimulating factor in CHO dhfr-cells: new insights into the in vitro amplification expression system; Gene (1996) Vol. 180 pages 145-150; Elsevier Science B.V.	
dw		RANDAL J. KAUFMAN; Selection and Coamplification of Heterologous Genes in Mammalian Cells; Methods in Enzymology (1990) Vol. 185 Pages 537-566; Academic Press	
dw		SUNG K. JANG ET AL; Initiation of Protein Synthesis by Internal Entry of Ribosomes into the 5' Nontranslated Region of Encephalomyocarditis Virus RNA In Vivo; Journal of Virology (April 1989) Vol. 63 No. 4 pages 1651-1660; American Society for Microbiology	
dw		KEITH D. HANSON ET AL; Analysis of Biological Selections for High-Efficiency Gene Targeting; Molecular and Cellular Biology (Jan. 1995) Vol. 15 No. 1 pages 45-51; American Society for Microbiology	
dw		MARTIN CHALFIE ET AL; Green Fluorescent Protein as a Marker for Gene Expression; Science (February 11, 1994) Vol. 263 pages 802-805;	

Examiner
Signature

M. Alivisatos

Date
Considered


03/06/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

4

of

4

Complete If Known

Application Number	10/724,301
Filing Date	November 26, 2003
First Named Inventor	Barbara Enenkel
Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	1/1411

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>dm</i>		MONIQUE V. DAVIES ET AL; The Sequence Context of the Initiation Codon in the Encephalomyocarditis Virus Leader Modulates Efficiency of Internal Translation Initiation; Journal of Virology April 1992 Vol. 66 No. 4 pages 1924-1932; American Society for Microbiology	
<i>dm</i>		D.L. BURK ET AL; Structural Analyses of Nucleotide Binding to an Aminoglycoside Phosphotransferase; Biochemistry 2001 Vol. 40 pages 8756-8764; American Chemical Society	
<i>dm</i>		ROBERT P. BENNETT ET AL; Fusion of Green Fluorescent Protein with the Zeocin TM-Resistance Marker Allows Visual Screening and Drug Selection of Transfected Eukaryotic Cells; Biotechniques March 1998 Vol. 24 No 3 pages 478-482; Invitrogen Corporation Carlsbad, Ca.	
<i>dm</i>		MOHAMMAED A ADAM ET AL; Internal Initiation of Translation in Retroviral Vectors Carrying Picornavirus 5' Nontranslated Regions; Journal of Virology September 1991 Vol. 65 No. 9 pages 4985-4990; American Society for Microbiology	
		WAI-CHING HON ET AL; Structure of an Enzyme Required for Aminoglycoside Antibiotic Resistance Reveals Homology to Eukaryotic Protein Kinases; Cell June 13, 1997 Vol. 89 pages 887-895; Cell Press	
		RICHARD L. YENOFISKY ET AL; A Mutant neomycin phosphotransferase II gene reduces the resistance of transformants to antibiotic selection pressure; Pro. Natl Acad. Science May 1990 Vol. 87, pages 3435-3439; Phytoen Pasadena, CA.	
		SEMRA KOCABIYIK ET AL; Site-Specific Mutations of Conserved C-Terminal Residues in Aminoglycoside 3'-Phosphotransferase II: Phenotypic and Structural Analysis of Mutant Enzymes; Biochemical and Biophysical Research Comm. June 1992 Vol. 185 No. 3 pages 925-931; Academic	
		J. BLAZQUEZ ET AL; Mutations in the α A-2 gene of transposon Tn5 mapping within the regions highly conserved in aminoglycoside-phosphotransferases strongly reduce aminoglycoside resistance; Molecular Microbiology 1991 Vol. 5 No. 6 pages 1511-1518	

Examiner
Signature

Initials

Date
Considered

03/06/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.